Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: A randomized clinical trial

JAMA Dermatology

Volumn 151, Issue 9, 2015, Pages 952-960

  Pomerantz, Hyemin ^a   Hogan, Daniel ^m,q   Eilers, David ^m,q   Swetter, Susan M ^m,q   Chen, Suephy C ^m,q   Jacob, Sharon E ^m,q   Warshaw, Erin M ^m,q   Stricklin, George ^b,c   Dellavalle, Robert P ^d   Sidhu Malik, Navjeet ^e,f   Konnikov, Nellie ^d   Werth, Victoria P ^d,g   Keri, Jonette ^h,i   Lew, Robert ^j,m   Weinstock, Martin A ^a,k,l,m   Marcolivio, Kimberly ^m   DiGiovanna, John J ^m   Ferguson, Ryan ^m   Ringer, Robert ^m   Yoon, Jean ^m   Phibbs, Ciaran S ^m   Kraemer, Ken ^m   Swan, James W ^m,q   Nord, Kristin ^m,q   Pollack, Brian ^m,q   Kempiak, Stephen ^m,q   High, Whitney ^m   Fett, Nicole ^m   Hall, Russell P ^m   Alonso Llamazares, Javier ^m   Rodriguez, Georgette ^m   Sisler, Lorine ^m,q   O'Sullivan, Mary ^m,q   Wilson, Sonya ^m,q   Agrawal, Madhuri ^m,q   Bartenfeld, Debra ^m,q   Nicalo, Keith ^m,q   Johnson, Deb ^m,q   Parks, Patricia ^m,q   Bidek, Barbara ^m   Boyd, Nancy ^m   Watson, Barbara ^m   Wolfe, Dianne ^m   Zacheis, Mark ^m   Okawa, Joyce ^m   Iannacchione, Mary Ann ^m   Quintero, Jalima ^m   Cuddapah, Subbarayudu ^m,q   Muller, Karen ^m,q   Lichon, Vanessa ^m,q   Anhalt, Todd ^m,q   Khosravi, Vista ^m,q   Rahman, Zakia ^m,q   Lawley, Leslie ^m,q   McCoy, Roberta ^m,q   Foman, Neal ^m,q   Bershow, Andrea ^m,q   Zic, John ^m   Miller, Jami ^m   Arbuckle, H Alan ^m   Hemphill, Linnea ^m   Fujita, Mayumi ^m   Norris, David ^m   Ramaswamy, Preethi ^m   Nevas, Jennifer ^m   Rao, Caroline H ^m   Gifford, Allen J ^m   Asher, Kelly A ^m   Cardones, Adela Rambi G ^m   Richardson, Angela F ^m   Patrick, Carmen Adams ^m   Fiore, Louis ⁿ   Ferguson, Ryan E ⁿ   Thwin, Soe Soe ⁿ   Kebabian, Clara E ⁿ   Pavao, Jennifer ⁿ   Sather, Mike ^o   Fye, Carol ^o   Hunt, David ^o   Robinson Bostom, Leslie ^p   Telang, Gladys ^p   Wilkel, Caroline ^p   Haynes, Harley A ^p   Brookhart, Maurice Alan ^p   Mostow, Eliot N ^p   Rector, Thomas ^p   more..

^a PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j Massachusetts Veterans Epidemiology and Research Information Center   (United States)

^k RHODE ISLAND HOSPITAL   (United States)

^l BROWN UNIVERSITY   (United States)

^m Study Deprtm man's Office   (United States)

ⁿ MAVERIC   (United States)

^o University of New Mexico   (United States)

^p Dermatopathologists   (United States)

^q Dermatopathologists ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PLACEBO; ANTINEOPLASTIC ANTIMETABOLITE;

ACTINIC KERATOSIS; ADULT; CONFERENCE PAPER; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN EXAMINATION; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; KERATOSIS, ACTINIC; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; SKIN; TIME; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KERATOSIS, ACTINIC; MALE; RETROSPECTIVE STUDIES; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84941275504     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.0502     Document Type: Conference Paper

References (18)

1. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115(11):2523-2530.
2. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013; 169(3):502-518.
3. Lee K, Weinstock M. Prospective quality of life impact of actinic keratoses: observations from the veterans affairs topical tretinoin chemoprevention trial. Acta Derm Venereol. 2011;91(1):101-102.
4. Goldenberg G, Perl M. Actinic keratosis: update on field therapy. J Clin Aesthet Dermatol. 2014;7 (10):28-31.
5. The Society for Investigative Dermatology and the American Academy of Dermatology Association. The Burden of Skin Diseases: 2005 [monograph on the Internet]. Falls Church, VA: The Lewin Group; 2005. http://www.lewin.com /~/media/Lewin/Site-Sections/Publications /april2005skindisease.pdf. Accessed December 10, 2014.
6. Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006; 32(8):1045-1049.
7. Perera E, McGuigan S, Sinclair R. Cost for the treatment of actinic keratosis on the rise in Australia [v2; ref status: indexed, http://f1000r.es/48f]. F1000 Res. 2014;3:184.
8. Hagele TJ, Levender MM, Davis SA, Williford PM, Feldman SR. Practice trends in the treatment of actinic keratosis in the United States: 0.5% fluorouracil and combination cryotherapy plus fluorouracil are underused despite evidence of benefit. J Cutan Med Surg. 2012;16(2): 107-114.
9. Nashan D, Meiss F, MüllerM. Therapeutic strategies for actinic keratoses-a systematic review. Eur J Dermatol. 2013;23(1):14-32.
10. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70(6): 335-339.
11. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002; 70(2)(suppl):22-29.
12. Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5%topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140(7): 813-816.
13. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5%fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5(2):133-139.
14. Korgavkar K, Firoz EF, Xiong M, et al; VAKCC Trial Group. Measuring the severity of topical 5-fluorouracil toxicity. J Cutan Med Surg. 2014;18 (4):229-235.
15. Lee KC, Lew R, Weinstock MA. Improvement in precision of counting actinic keratoses. Br J Dermatol. 2014;170(1):188-191.
16. Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415.
17. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5%fluorouracil cream and 5%fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24(6):990-1000.
18. Chen SC, Hill ND, Veledar E, Swetter SM, Weinstock MA. Reliability of quantification measures of actinic keratosis. Br J Dermatol. 2013; 169(6):1219-1222.